stedutazumab

Stedutazumab is a recombinant human monoclonal antibody (IgG1-kappa) developed for the rapid prophylaxis of tetanus. It specifically targets and neutralizes tetanospasmin, the potent neurotoxin produced by *Clostridium tetani* that causes the muscle spasms and autonomic instability characteristic of tetanus. As a recombinant product, stedutazumab serves as a standardized alternative to traditional human tetanus immune globulin (HTIG), which is derived from human plasma and carries risks of supply variability and potential pathogen transmission. The drug has been evaluated in clinical settings in China, including Phase 4 studies comparing its safety and onset of action to traditional HTIG in adults requiring emergency tetanus prevention. It was approved by the NMPA in China in early 2024.

Other names

stedutazumabrecombinant human anti-tetanus toxin monoclonal antibody司特度单抗